REAL-WORLD DATA (RWD) / REAL-WORD EVIDENCE (RWE) INSIGHTS
-
RWE Is Growing Up, And Here's Why That Matters
Real-world evidence is shifting from the margins to the mainstream of drug development, but data quality, trust, and regulatory clarity remain hurdles. ISPOR is helping set the standards to guide its future.
-
Combining RWD And Machine Learning To Determine Meaningful Patient Populations
Combining RWD with advanced ML models offers a powerful and transformative solution to optimize patient recruitment.
RWD/RWE RESOURCES
-
One Day, We Won't Need Placebos
Embrace the future of clinical research by recognizing the limitations of traditional double-blind trials and exploring the transformative potential of real-world evidence (RWE).
-
Accelerating Innovation In Clinical Trials With Real-World Data
Learn about the challenge to access and connect to real-world data (RWD) – including EHR, claims, lab, and other data types once patient data is de-identified for trial purposes.
-
Trends Shaping The Pharmaceutical Industry's Future
Decentralized trials and patient choice are key to expanding study reach. Here, we examine how patient access increases with diverse options and AI-powered connections across health systems and sites.
-
Do We Still Need Patients In Tomorrow's Trials?
Delve into how advanced technologies reshape drug development and patient care, and the crucial balance needed between innovation and ethical responsibility to achieve better trial outcomes.
-
5 Ways Lab Data Can Help Commercialize Your Therapy
Delve into five pivotal insights for leveraging lab data effectively and the collaboration that accelerated market entry for new therapies while ensuring the needs of targeted populations were met.
-
Pitfalls And Possibilities: EHRs To RWD Via EDC
Consider DIA GCP & QA Community Chair Terry Katz’s perspective on repurposing and analyzing EHR data for clinical research.
-
Optimizing Clinical Trials: Getting The Right Results By Keeping it Real
Biopharma companies and CROs can utilize real-world data to better reflect real-world populations in clinical trials, optimizing protocol design,site selection, and patient matching.